Tetra Radar · FDA Approvals · Decision date
bictegravir: FDA decision date
Gilead Sciences Inc (GILD) · 2 February 2027
Announced FDA accepted a supplemental New Drug Application (“NDA”) submission for Yeztugo 300-mg tablet as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis, with a Prescription Drug User Fee Act (“PDUFA”) target action date of February 2, 2027.
Source: 10-Q of 30 October 2026
The decision is pending.
Gilead Sciences Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.